The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

@article{Tam2007TheNH,
  title={The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.},
  author={Constantine S. Tam and Susan O'brien and Susan Lerner and Issa F. Khouri and Alessandra Ferrajoli and Stefan H. Faderl and Mary Ann Browning and Apostolia-Maria Tsimberidou and Hagop A Kantarjian and William G Wierda},
  journal={Leukemia & lymphoma},
  year={2007},
  volume={48 10},
  pages={1931-9}
}
The natural history and outcome of salvage treatment for patients with fludarabine-refractory chronic lymphocytic leukemia who are either refractory to alemtuzumab ("double-refractory") or ineligible for alemtuzumab due to bulky lymphadenopathy ("bulky fludarabine-refractory") have not been described. We present the outcomes of 99 such patients (double-refractory n = 58, bulky fludarabine-refractory n = 41) undergoing their first salvage treatment at our center. Patients received a variety of… CONTINUE READING